Media.Player

Transfusion-related acute lung injury (TRALI) Screening

技术优势

Prevention of death related to TRALI.

技术应用

Screening of donors for TRALI antibodies.

详细技术说明

For decades, human neutrophil antigen (HNA) HNA-3a was thought to be involved in the condition known as Transfusion-related acute lung injury (TRALI); currently the leading cause of transfusion-related mortality reported to the FDA. However, until recently, little was known about the specific properties of HNA-3a. BloodCenter inventors, Brian Curtis and Dick Aster, have been working to identify the molecular properties of the HNA-3a or ΓÇ£5bΓÇØ antigen and its role in fatal TRALI. They identified the carrier protein for HNA-3a and determined the molecular basis of the HNA-3a/b polymorphism.Work in progress will facilitate low cost, large scale typing of donor populations to identify persons who are HNA-3a negative (5% of the general population). Blood donor typing will identify those who are at risk to have HNA-3a-specific antibodies. Methods should enable detection of antibodies specific for HNA-3b, the incidence and significance of which is not yet known.Patent pending

*Abstract

For decades, human neutrophil antigen (HNA) HNA-3a was thought to be involved in the condition known as Transfusion-related acute lung injury (TRALI); currently the leading cause of transfusion-related mortality reported to the FDA.

*Principal Investigation

Name: Brian Curtis

Department:

Name: Richard Aster

Department:

国家/地区

美国